Brief: Anixa Biosciences Announces Treatment Of Second Patient In Its Ovarian Cancer Car-T Clinical Trial
22/05/2023 14:52
May 22 (Reuters) - Anixa Biosciences Inc ANIX.O :
* ANIXA BIOSCIENCES ANNOUNCES TREATMENT OF SECOND PATIENT IN
ITS
OVARIAN CANCER CAR-T CLINICAL TRIAL
* ANIXA BIOSCIENCES-COMMENCED TREATMENT OF SECOND PATIENT IN
ONGOING CLINICAL TRIAL OF NOVEL CHIMERIC ANTIGEN RECEPTOR T-CELL
THERAPY FOR OVARIAN CANCER
Source text for Eikon: ID:nPn1dDxv5a
Further company coverage: ANIX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Anixa Biosciences
See all newsBrief: Anixa Biosciences Announces First Case Of Stable Disease For Three Months In Ovarian Cancer Car-T Clinical Trial
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Anixa Biosciences Inc reports results for the quarter ended July 31 - Earnings Summary
Anixa Biosciences Inc expected to post a loss of 9 cents a share - Earnings Preview
Factbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine